New malaria drug requires just one dose and appears twice as effective as existing regimen

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Scientists are reporting development of a new malaria drug that, in laboratory tests, has been twice as effective as the best current medicine against this global scourge and may fight off the disease with one dose, instead of the multiple doses that people often fail to take. A report on the drug appears in ACS’ Journal of Medicinal Chemistry.

Gary Posner and colleagues explain that malaria continues to kill almost 1 million people annually. The best existing treatment is so-called artemisinin combination therapy (ACT). It requires patients to take pills every day for several days, and many patients fail to complete the regimen. As a result, these patients don’t get better, and it opens the door for malaria parasites to develop resistance to ACT. To stop that from happening, the researchers developed a new type of ACT that could stop malaria in a single dose.

They describe a series of new compounds they developed that, given once, are more effective than traditional artemisinin-derived substances. One of the new compounds, when combined with mefloquine, killed off all of the parasites in some mice with just a single oral dose and allowed those mice to live almost twice as long as those treated with conventional ACT.

The authors acknowledge funding from the National Institutes of Health, the Johns Hopkins Malaria Research Institute and the Bloomberg Family Foundation.

 

Latest stories

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back